Clinical trials: Mild-to-moderate Ulcerative Colitis
Ulcerative Colitis (UC)
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
- Trial name
- NCT06749795
- Testing
- LIV001
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Liveome Inc.
Ulcerative Colitis
Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis
Based on the efficacy of inulin and oligofructose in treating experimental colitis and emerging evidence suggesting probiotics are efficacious in maintaining and inducing remission in human ulcerative colitis (UC), the…
- Trial name
- NCT02093767
- Testing
- Synergy1
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University of Alberta
Ulcerative Colitis
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis
Approximately 45 patients suffering from mild to moderate ulcerative colitis will be examined for any side effects (safety and tolerability) that may occur when taking GLPG0974 or matching placebo (2:1 ratio) for 28 days.
- Trial name
- NCT01829321
- Testing
- GLPG0974
- Where
- 16 sites in Belgium, Czechia and 2 more
- Volunteers
- 45 people
- Sponsor
- Lakefront Biotherapeutics NV
Ulcerative Colitis
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.
- Trial name
- NCT04898348
- Testing
- KBL697
- Where
- Australia
- Sponsor
- KoBioLabs
Ulcerative Colitis
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
- Trial name
- NCT02618187
- Testing
- SER-287, Vancomycin Pre-Treat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Seres Therapeutics, Inc.
Colitis, Ulcerative
Confirmatory Clinical Study in Active Ulcerative Colitis
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects.
- Trial name
- StarFish-UC (NCT07296315)
- Testing
- Low-dose MH002, High-dose MH002
- Where
- 49 sites in United States, Czechia and 5 more
- Volunteers
- 204 people
- Sponsor
- MRM Health NV
Ulcerative Colitis
A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)
This study is only for the first in human phase 1a study designed to investigate the safety and tolerability of LIV001 in healthy participants.
- Trial name
- NCT05975047
- Testing
- LIV001
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Liveome Inc.
Ulcerative Colitis (UC)
Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the colonic mucosa. Despite advances in therapeutic options, many patients experience incomplete remission or treatment…
- Trial name
- NCT07820046
- Testing
- Nitazoxanide (NTZ)
- Volunteers
- 44 people
- Sponsor
- Tanta University
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Fecal Transplantation Using a Diet for Donor and Recipient in Refractory Colitis
Changing the microbiota has become the most intriguing target for intervention in inflammatory bowel disease (IBD). Dietary therapy is successful in mild to moderate Crohn's disease and may be effective in mild to moderate…
- Trial name
- NCT02734589
- Testing
- Fecal transplantation, Unique novel Diet for UC and Unique novel Diet for the donor + FMT, Unique novel Diet for UC
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 54 people
- Sponsor
- Wolfson Medical Center
Ulcerative Colitis (UC)
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum, characterized by mucosal inflammation and symptomslike diarrhea, abdominal pain, and rectal bleeding.
- Trial name
- ALTER-UC (NCT06895252)
- Testing
- Anti inflammatory diet, Fecal Microbial Transplantation
- Where
- 6 sites in India
- Volunteers
- 220 people
- Sponsor
- All India Institute of Medical Sciences
Colitis, Ulcerative
An Early Phase 2 Clinical Study of KSP-0243
A phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to administer KSP-0243 or a placebo once daily after breakfast for 8 weeks in 100 patients with mild to moderate active ulcerative…
- Trial name
- NCT05831670
- Testing
- KSP-0243
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Colitis, Ulcerative
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.
- Trial name
- NCT03412682
- Testing
- Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg)
- Where
- 72 sites in Japan
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis
This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis.
- Trial name
- NCT02768974
- Testing
- OPRX-106
- Where
- 7 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Protalix
Mild to Moderate Ulcerative Colitis
Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
A clinical trial is being conducted to test the effects of a potential new treatment in patients with ulcerative colitis. Study participants will be given capsules containing either ORE1001 or a matching placebo capsule and will…
- Trial name
- NCT01039597
- Testing
- ORE1001
- Where
- 7 sites in Canada, India
- Volunteers
- 50 people
- Sponsor
- Ore Pharmaceuticals, Inc.
Active Ulcerative Colitis, Remission of Ulcerative Colitis
Canadian Active & Maintenance Modified Pentasa Study
The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative…
- Trial name
- CAMMP (NCT00603733)
- Testing
- 5-ASA (5-Aminosalicylate)
- Where
- 27 sites in Canada
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Proctitis, Ulcerative
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories (MAX-002) as compared to placebo and…
- Trial name
- NCT01016262
- Testing
- MAX-002, Canasa®
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 119 people
- Sponsor
- Forest Laboratories
Ulcerative Colitis
Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative…
- Trial name
- NCT01059344
- Testing
- Mesalamin
- Where
- 31 sites in Belarus, India and 2 more
- Volunteers
- 281 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
Microbiota-targeted Diet for Pediatric UC
Ulcerative colitis is a chronic inflammatory disease primarily involving the colon and has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors.
- Trial name
- UCD (NCT02922881)
- Testing
- Ulcerative Colitis Diet (UCD)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital of Philadelphia